Modulation of Pituitary Somatostatin Receptor Subtype (sst1-5) mRNA Levels by Growth Hormone (GH) -Releasing Hormone in Purified Somatotropes.
- Author:
Seungjoon PARK
1
;
Heesoon PARK
;
Mina LEE
;
Sookjin SOHN
;
Eunhee KIM
;
Jeechang JUNG
;
Lawrence A FROHMAN
;
Rhonda D KINEMAN
Author Information
1. Department of Pharmacology, Kyunghee University School of Medicine, Seoul 130 701, Korea. sjpark@khu.ac.kr
- Publication Type:In Vitro ; Original Article
- Keywords:
GHRH;
Forskolin;
Somatostatin receptor;
Somatotrope;
cAMP;
Adenylyl cyclase
- MeSH:
Adenylyl Cyclases;
Cell Culture Techniques;
Colforsin;
Goats;
Growth Hormone*;
Haplorhini;
Immunoglobulin G;
Immunohistochemistry;
Masks;
Membranes;
Receptors, Somatostatin*;
RNA;
RNA, Messenger*;
Somatostatin*
- From:The Korean Journal of Physiology and Pharmacology
2003;7(2):79-84
- CountryRepublic of Korea
- Language:English
-
Abstract:
We have previously reported that expression of the somatostatin receptor subtypes, sst1-5, is differentially regulated by growth hormone (GH) -releasing hormone (GHRH) and forskolin (FSK), in vitro. GHRH binds to membrane receptors selectively located on pituitary somatotropes, activates adenylyl cyclase (AC) and increases sst1 and sst2 and decreases sst5 mRNA levels, without significantly altering the expression of sst3 and sst4. In contrast FSK directly activates AC in all pituitary cell types and increases sst1 and sst2 mRNA levels and decreases sst3, sst4 and sst5 expression. Two explanations could account for these differential effects: 1) GHRH inhibits sst3 and sst4 expression in somatotropes, but this inhibitory effect is masked by expression of these receptors in unresponsive pituitary cell types, and 2) FSK inhibits sst3 and sst4 expression levels in pituitary cell types other than somatotropes. To differentiate between these two possibilities, somatotropes were sequentially labeled with monkey anti-rat GH antiserum, biotinylated goat anti-human IgG, and streptavidin-PE and subsequently purified by fluorescent-activated cell sorting (FACS). The resultant cell population consisted of 95% somatotropes, as determined by GH immunohistochemistry using a primary GH antiserum different from that used for FACS sorting. Purified somatotropes were cultured for 3 days and treated for 4 h with vehicle, GHRH (10 nM) or FSK (10micrometer). Total RNA was isolated by column extraction and specific receptor mRNA levels were determined by semi-quantitative multiplex RT-PCR. Under basal conditions, the relative expression levels of the various somatostatin receptor subtypes were sst2> sst5> sst3=sst1> sst4. GHRH treatment increased sst1 and sst2 mRNA levels and decreased sst3, sst4 and sst5 mRNA levels in purified somatotropes, comparable to the effects of FSK on purified somatotropes and mixed pituitary cell cultures. Taken together, these results demonstrate that GHRH acutely modulates the expression of all somatostatin receptor subtypes within GH-producing cells and its actions are likely mediated by activation of AC.
